Articles from Syntax Bio

Syntax Bio, a synthetic biology company programming the next generation of cell therapies, today announced an expanded Series A and new appointments to its executive leadership team, board of directors and scientific advisory board. The expansion brings Syntax Bio’s Series A to $14.4 million and total funding to over $25 million.

Syntax Bio, a synthetic biology company programming next generation cell therapies, today announced a research and development collaboration with Mayo Clinic focused on advancing stem cell-derived pancreatic cell therapies for type 1 diabetes.

Syntax Bio, a synthetic biology company programming the next generation of cell therapies, today announced it has received an award of up to $856,250 from Breakthrough T1D, the leading global type 1 diabetes (T1D) research and advocacy organization, under its Industry Discovery and Development Partnership (IDDP) program to advance a pancreatic beta cell therapy targeting T1D using its Cellgorithm platform technology.

Syntax Bio, a synthetic biology company programming the next generation of cell therapies, today announced the publication of new research in Science Advances detailing the company’s CRISPR-based Cellgorithm™ technology, which lays the groundwork for programmable control of gene activity in human stem cells and offers an alternative to the slow, variable manual processes researchers use today.

Syntax Bio, a preclinical-stage biotechnology company, has launched with backing from Astellas Venture Management LLC and Illumina Ventures. Other investors include DCVCBio, Civilization Ventures, EGB Capital, and Portal Innovations.